A ketogenic diet may reduce the severity of psychotic symptoms in patients with schizophrenia, according to the first randomized controlled trial (RCT) of its kind. The study, published in Psychiatry Research, found that participants following a ketogenic diet alongside standard antipsychotic medication experienced significant improvements in positive and negative symptoms compared to a control group following a standard diet.
Ketogenic Diet Impacts on Schizophrenia Symptoms
The research indicates that a ketogenic diet—a high-fat, very-low-carbohydrate regimen—can serve as an effective adjunctive therapy for psychotic disorders. According to the study findings, patients on the ketogenic protocol showed a marked decrease in the Positive and Negative Syndrome Scale (PANSS) scores, which clinicians use to measure the severity of schizophrenia symptoms.
Researchers focused on the “metabolic psychiatry” aspect of the treatment. This approach targets the underlying metabolic dysfunction often seen in patients with schizophrenia, such as insulin resistance and mitochondrial dysfunction. By shifting the body’s primary energy source from glucose to ketones, the diet may stabilize brain energy metabolism and reduce neuroinflammation, according to the National Center for Biotechnology Information (NCBI).
How the Randomized Controlled Trial Was Conducted
The trial utilized a rigorous design to isolate the effects of the diet from other variables. Participants were split into two groups: one following a strict ketogenic diet and another following a conventional diet. Both groups continued their prescribed antipsychotic medications to ensure patient safety and stability.
Key parameters of the study included:
- Dietary Adherence: Participants were monitored for ketone levels in the blood to verify they remained in a state of nutritional ketosis.
- Symptom Tracking: Researchers used standardized psychiatric scales to track changes in hallucinations, delusions, and social withdrawal.
- Metabolic Markers: The team measured changes in blood glucose and insulin sensitivity to correlate metabolic health with psychiatric improvement.
Metabolic Psychiatry and the Brain-Energy Connection
The link between metabolism and mental health is rooted in how the brain consumes fuel. Many patients with schizophrenia exhibit “cerebral glucose hypometabolism,” a condition where the brain doesn’t use glucose efficiently. According to research published in The Lancet Psychiatry, ketones provide an alternative fuel source that can bypass these glucose deficits.
This shift in fuel may improve the function of glutamate and GABA—the brain’s primary excitatory and inhibitory neurotransmitters. When these chemicals are imbalanced, it often results in the cognitive fragmentation and sensory distortions characteristic of psychosis.
Comparing Ketogenic Therapy to Standard Care
| Feature | Standard Care (Medication Only) | Adjunctive Ketogenic Therapy |
|---|---|---|
| Primary Mechanism | Dopamine/Serotonin modulation | Metabolic shift + Neurotransmitter balance |
| Metabolic Effect | Risk of weight gain/insulin resistance | Improved insulin sensitivity |
| Symptom Target | Acute psychotic symptoms | Both acute symptoms and metabolic dysfunction |
Safety Considerations and Medical Supervision
Medical professionals warn that a ketogenic diet should not be attempted by patients with psychotic disorders without strict clinical supervision. The diet can cause significant changes in how the body processes medication, and some antipsychotics can exacerbate metabolic issues if not managed carefully.
Potential risks include “keto flu” during the transition phase and the possibility of nutrient deficiencies. According to the Mayo Clinic, a supervised approach ensures that electrolyte levels remain stable and that the diet does not interfere with the efficacy of psychiatric drugs.
Future Outlook for Psychotic Disorder Treatment
This RCT provides a foundation for larger, multi-center trials to determine if ketogenic therapy can reduce the required dosage of antipsychotic medications, potentially lowering the risk of long-term side effects. As the field of metabolic psychiatry grows, the integration of nutritional interventions with pharmacological treatment may become a standard of care for treatment-resistant schizophrenia.
Related reading